ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Seaport Therapeutics, a start-up developing psychiatric treatments, has raised $225 million in a series B funding round—for a total of $325 million since its launch in April. The company’s Glyph technology directs its drug candidates to the lymphatic system instead of the liver, a change that should decrease toxicity and increase bioavailability. Seaport’s lead candidate is SPT-300, a prodrug of allopregnanolone that is currently in Phase 2b trials to treat major depression. Investors include ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and PureTech Health, which cofounded the firm.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter